Cerebral neoplastic enhancing lesions: Multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1mmolGd/kg body weight in a clinical setting

Are There Differences between Macrocyclic Gadolinium Contrast Agents for Brain Tumor Imaging? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol with Gadoteridol (the TRUTH Study)

“…On the other hand, this population size and the number of confirmed tumors evaluated (n ϭ 246) are comparable with previous intraindividual comparisons of GBCAs for brain tumor imaging [14][15][16] and should be sufficiently robust to provide a true reflection of the comparable performance of these 2 GBCAs. Additionally, a second limitation is that advanced imaging techniques (eg, perfusion, diffusion, and functional techniques) were not performed.…”

The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study)

“…In this study, we determined larger differences in percentage lesion enhancement and LBR of 27.6%-31.7% and 29.2%-38.1%, respectively, for equivalent doses of gadobenate and gadoterate, which reflect the still greater difference in r1 relaxivity of ϳ59%. Notably, in the study by Anzalone et al, 11 the slightly greater r1 relaxivity of gadobutrol compared with gadoterate led to improved imaging performance for gadobutrol for some, though not all, qualitative end points, and not all blinded readers demonstrated significant preference for gadobutrol.…”

“…5 That differences in r1 relaxivity reflect differences in diagnostic efficacy is borne out by evidence from numerous large-scale intraindividual crossover studies. [1][2][3][4][8][9][10][11] These studies have shown that differences in SI enhancement and imaging performance reflect differences in r1 relaxivity and that the magnitude of the differences in SI enhancement a Comparisons based on the number of patients with both postdose T1SE images assessed and technically adequate: n ϭ 96 for reader 1, n ϭ 94 for reader 2, and n ϭ 95 for reader 3. Numbers in parentheses, except where noted, represent proportions of patients.…”

Time-Dependent Changes in the Magnetic Resonance Detection of Brain Metastases Using Single-Dose Gadobutrol

“…However, early detection of small lesions is very critical for clinical staging and treatment planning (5,19). A number of studies performed to study the effect of highdose contrast agents have demonstrated enhanced lesion detection in patients with brain metastases compared to low-dose contrast agents (12,20). To date, the available studies have used linear structured Gd-DTPA and there are no studies that have used circular structured gadobutrol.…”

“…Additionally, gadobutrol has an inherently higher T1 relaxivity than Gd-DTPA (8)(9)(10)(11). Results from animal and human studies have demonstrated an increased detection of metastatic brain lesions by gadobutrol because of its higher concentration and relaxivity compared with the same dose of Gd-DTPA (12)(13)(14). However, there are limited studies that have evaluated different delay times of gadobutrol (8,15).…”